Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zelenirstat - PACYLEX PHARMACEUTICALS

Next Previous
Drug Profile

Zelenirstat - PACYLEX PHARMACEUTICALS

Alternative Names: DDD-86481; PCLX-001

Latest Information Update: 24 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Dundee
  • Developer PACYLEX PHARMACEUTICALS
  • Class Aminopyridines; Antineoplastics; Benzene derivatives; Chlorinated hydrocarbons; Piperazines; Pyrazoles; Pyridines; Radiosensitisers; Small molecules; Sulfonamides
  • Mechanism of Action Glycylpeptide N-tetradecanoyltransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Phase II Colorectal cancer; Non-Hodgkin's lymphoma
  • Phase I/II Solid tumours
  • Phase I Acute myeloid leukaemia
  • Preclinical Glioblastoma

Most Recent Events

  • 03 Mar 2025 Phase-I clinical trials in Acute myeloid leukaemia (Second-line therapy or greater) in USA (PO) (NCT06613217)
  • 28 Oct 2024 Pacylex Pharmaceuticals completesa a phase I clinical trials in Solid tumours and Non-Hodgkin's lymphoma (Late-stage disease, Second-line therapy or greater) in Canada (PO) (NCT04836195)
  • 25 Sep 2024 Pacylex Pharmaceuticals plans a phase I trial for Acute myeloid leukemia (Second-line therapy or greater) in October 2024 (PO) (NCT06613217)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top